Tyrosine kinase inhibitors and modifications of thyroid function tests: a review

Illouz, Frédéric; Laboureau-Soares, Sandrine; Dubois, Séverine; Rohmer, Vincent; Rodien, Patrice

doi:10.1530/eje-08-0648

Cited by 77Thyroid Disorders and TreatmentsThyroid and Parathyroid SurgeryThyroid Cancer Diagnosis and Treatment

Tyrosine kinase inhibitors and modifications of thyroid function tests: a review

Illouz, Frédéric, Laboureau-Soares, Sandrine, Dubois, Séverine, Rohmer, Vincent, Rodien, Patrice·2009·European Journal of Endocrinology

DOI 10.1530/eje-08-0648

Open this paper in CoChat — free account

Abstract

Tyrosine kinase inhibitors (TKI) belong to new molecular multi-targeted therapies that are approved for the treatment of haematological and solid tumours. They interact with a large variety of protein tyrosine kinases involved in oncogenesis. In 2005, the first case of hypothyroidism was described and since then, some data have been published and have confirmed that TKI can affect the thyroid function tests (TFT). This review analyses the present clinical and fundamental findings about the effects of TKI on the thyroid function. Various hypotheses have been proposed to explain the effect of TKI on the thyroid function but those are mainly based on clinical observations. Moreover, it appears that TKI could alter the thyroid hormone regulation by mechanisms that are specific to each molecule. The present propositions for the management of TKI-induced hypothyroidism suggest that we assess the TFT of the patients regularly before and during the treatment by TKI. Thus, a better approach of patients with TKI-induced hypothyroidism could improve their quality of life.

Integrity signals

Registry

Crossref · 10.1530/eje-08-0648

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Increased levothyroxine requirements have been reported in hypothyroid patients who start oestrogen replacement therapy or receive tyrosine kinase inhibitors.
“Increased levothyroxine requirements have been reported in hypothyroid patients who start oestrogen replacement therapy or receive tyrosine kinase inhibitors.155”
From Hypothyroidism (2024) · cites this paper as [155]

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017 · see citing works
Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5
Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D. P., Wilhelm, S. M., Lynch, M. J., & Carter, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1377 · Cited by 1,539 · see citing works
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Etten, R. A. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,376 · see citing works
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkelä, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L. L. H., Woulfe, K. C., Pravda, E. A., Cassiola, F. M., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,081 · see citing works
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Kamba, T., Tam, B. Y. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., Norberg, S. M., O’Brien, S., Davis, R. B., Gowen, L. C., et al. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00133.2005 · Cited by 773 · see citing works
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
Eisen, T. G., Ahmad, T., Flaherty, K. T., Gore, M. E., Kaye, S. B., Marais, R., Gibbens, I., Hackett, S., James, M., Schuchter, L. M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603291 · Cited by 638 · see citing works
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Sherman, S. I., Wirth, L. J., Droz, J.-P., Hofmann, M., Bastholt, L., Martins, R. G., Licitra, L., Eschenberg, M. J., Sun, Y.-N., Juan, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075853 · Cited by 470 · see citing works
Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
Desai, J., Yassa, L., Marqusee, E., George, S., Frates, M. C., Chen, M. H., Morgan, J. A., Dychter, S. S., Larsen, P. R., Demetri, G. D., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-9-200611070-00008 · Cited by 402 · see citing works
Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Rini, B. I., Tamaskar, I., Shaheen, P., Salas, R. N., Garcia, J., Wood, L. S., Reddy, S. S. K., Dreicer, R., & Bukowski, R. M. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk008 · Cited by 378 · see citing works
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling
Baffert, F., Le, T., Sennino, B., Thurston, G., Kuo, C. J., Hu‐Lowe, D. D., & McDonald, D. M. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00616.2005 · Cited by 374 · see citing works
AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor Xenografts
Polverino, A. J., Coxon, A., Starnes, C. O., Diaz, Z., DeMelfi, T. M., Wang, L., BREADY, J. V., Estrada, J., Cattley, R. C., Kaufman, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4665 · Cited by 286 · see citing works
Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma
Rock, E. P., Goodman, V. L., Jiang, J. X., Mahjoob, K., Verbois, S. L., Morse, D. E., Dagher, R. N., Justice, R. L., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-107 · Cited by 247 · see citing works
A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine Uptake
Mannavola, D., Coco, P., Vannucchi, G. M., Bertulli, R., Carletto, M., Casali, P. G., Beck‐Peccoz, P., & Fugazzola, L. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0586 · Cited by 227 · see citing works
Alternate Pathways of Thyroid Hormone Metabolism
Wu, S.-Y., Green, W. L., Huang, W.-S., Hays, M. T., & CHOPRA, I. J. (2005) · Thyroid · doi:10.1089/thy.2005.15.943 · Cited by 207 · see citing works
Sunitinib Induces Hypothyroidism in Advanced Cancer Patients and May Inhibit Thyroid Peroxidase Activity
Wong, E., Rosen, L. S., Mulay, M., VanVugt, A., Dinolfo, M., Tomoda, C., Sugawara, M., & Hershman, J. M. (2007) · Thyroid · doi:10.1089/thy.2006.0308 · Cited by 206 · see citing works
The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
Wolter, P., Stefan, C., Decallonne, B., Dumez, H., Bex, M., Carmeliet, P., & Schöffski, P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604497 · Cited by 198 · see citing works
Pathways of thyroid hormone metabolism.
Visser, T. J. (1996) · PubMed · Cited by 190 · see citing works
Safety, Pharmacokinetics, and Efficacy of AMG 706, an Oral Multikinase Inhibitor, in Patients With Advanced Solid Tumors
Rosen, L. S., Kurzrock, R., Mulay, M., Vugt, A. V., Purdom, M., Ng, C. S., Silverman, J., Koutsoukos, A. D., Sun, Y., Bass, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8170 · Cited by 187 · see citing works
A Phase II Trial of Imatinib Therapy for Metastatic Medullary Thyroid Carcinoma
de Groot, J. W. B., Zonnenberg, B. A., van Ufford-Mannesse, P. Q., de Vries, M. M., Links, T. P., Lips, C. J. M., & Voest, E. E. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0649 · Cited by 179 · see citing works
Imatinib induces hypothyroidism in patients receiving levothyroxine
DEGROOT, J., ZONNENBERG, B., PLUKKER, J., VANDERGRAAF, W., & LINKS, T. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.010 · Cited by 159 · see citing works
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
Tamaskar, I., Bukowski, R. M., Elson, P. J., Ioachimescu, A. G., Wood, L., Dreicer, R., Mekhail, T. M., Garcia, J., & Rini, B. I. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm483 · Cited by 147 · see citing works
Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice
Kim, S., Yazici, Y. D., Calzada, G., Wang, Z.-Y., Younes, M. N., Jasser, S. A., El‐Naggar, A. K., & Myers, J. N. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0595 · Cited by 138 · see citing works
Interferon-α-Related Thyroid Disease: Pathophysiological, Epidemiological, and Clinical Aspects
Carella, C., Mazziotti, G., Amato, G., Braverman, L., & Roti, E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0627 · Cited by 132 · see citing works
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
Chi, K. N., Ellard, S. L., Hotte, S. J., Czaykowski, P. M., Moore, M. J., Ruether, J. D., Schell, A. J., Taylor, S., Hansen, C., Gauthier, I., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm554 · Cited by 119 · see citing works
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma
Grossmann, M., Premaratne, E., Desai, J., & Davis, I. D. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03253.x · Cited by 109 · see citing works
Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization
Viglietto, G., Romano, A., Manzo, G., Chiappetta, G., Paoletti, I., Califano, D., Galati, M. G., Mauriello, V., Bruni, P., Lago, C. T., et al. (1997) · Oncogene · doi:10.1038/sj.onc.1201456 · Cited by 105 · see citing works
TSH-activated signaling pathways in thyroid tumorigenesis
Rivas, M., & Santisteban, P. (2003) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2003.10.029 · Cited by 97 · see citing works
Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases
Jebreel, A., England, J. A., Bedford, K., et al. (2007) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2007.00533.x · Cited by 95 · see citing works
New developments in multitargeted therapy for patients with solid tumours
Tourneau, C. L., Faivre, S. J., & Raymond, É. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.09.003 · Cited by 79 · see citing works
Thyrotropin (TSH)-Induced Production of Vascular Endothelial Growth Factor in Thyroid Cancer Cellsin Vitro: Evaluation of TSH Signal Transduction and of Angiogenesis-Stimulating Growth Factors
Hoffmann, S., Hofbauer, L. C., Scharrenbach, V., Wunderlich, A., Hassan, I., Lingelbach, S., & Zielke, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1260 · Cited by 75 · see citing works
Effect of Sunitinib on Growth and Function of FRTL-5 Thyroid Cells
Salem, A. K., Fenton, M. S., Marion, K. M., & Hershman, J. M. (2008) · Thyroid · doi:10.1089/thy.2007.0336 · Cited by 54 · see citing works
Sunitinib (Sutent)-Induced Thyrotoxicosis Due to Destructive Thyroiditis: A Case Report
Faris, J. E., Moore, A. F., & Daniels, G. H. (2007) · Thyroid · doi:10.1089/thy.2007.0104 · Cited by 54 · see citing works
Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC)
Wolter, P., Stefan, C., Decallonne, B., Dumez, H., Fieuws, S., Wildiers, H. P. M. W., Clément, P. M., Debaere, D., van Oosterom, A., & Schöffski, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5126 · Cited by 47 · see citing works
Iodide Inhibits Vascular Endothelial Growth Factor-A Expression in Cultured Human Thyroid Follicles: A Microarray Search for Effects of Thyrotropin and Iodide on Angiogenesis Factors
Yamada, E., Yamazaki, K., Takano, K., Obara, T., & Sato, K. (2006) · Thyroid · doi:10.1089/thy.2006.16.545 · Cited by 38 · see citing works
Selective Modulation of Protein Kinase A I and II Reveals Distinct Roles in Thyroid Cell Gene Expression and Growth
Calebiro, D., de Filippis, T., Lucchi, S., Martínez, F. O., Porazzi, P., Trivellato, R., Locati, M., Beck‐Peccoz, P., & Persani, L. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0493 · Cited by 38 · see citing works
Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients
Dora, J. M., Leie, M. A., Netto, B., Fogliatto, L. M., Silla, L. M. D. R., Torres, F. S., & Maia, A. L. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0006 · Cited by 33 · see citing works
Unanswered questions regarding the management of sunitinib-induced hypothyroidism
Garfield, D. H., Hercbergs, A. H., & Davis, P. J. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0998 · Cited by 30 · see citing works
Documentation of Thyroid Function in Clinical Studies With Sunitinib: Why Does It Matter?
Garfield, D. H., Wolter, P., Schöffski, P., Hercbergs, A. A., & Davis, P. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8680 · Cited by 21 · see citing works
Gestational Choriocarcinoma Mimicking a Uterine Adenocarcinoma
Patten, D. K., Lindsay, I., Fisher, R. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4129 · Cited by 19 · see citing works
Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma
Gupta, V., Puttaswamy, K., Lassoued, W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.6019 · Cited by 17 · see citing works

Flagged first, then by citations

Sorted by citations

Hypothyroidism
Taylor, P. N., Medici, M. M., Hubalewska-Dydejczyk, A., & Boelaert, K. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01614-3 · Cited by 128 · see citing works
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117 · see citing works
Thyroxine replacement: a clinical endocrinologist’s viewpoint
Eligar, V, Taylor, P., Okosieme, O., Leese, G., & Dayan, C. (2016) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563216642255 · Cited by 72 · see citing works
New therapies for dedifferentiated papillary thyroid cancer
Fallahi, P., Mazzi, V., Vita, R., Ferrari, S., Materazzi, G., Galleri, D., Benvenga, S., Miccoli, P., & Antonelli, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036153 · Cited by 58 · see citing works
Thyroid dysfunctions induced by tyrosine kinase inhibitors
Fallahi, P., Ferrari, S. M., Vita, R., Di Domenicantonio, A., Corrado, A., Benvenga, S., & Antonelli, A. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.913021 · Cited by 60 · see citing works

Susquehanna Chorale Spring Concert "Roots and Wings"
Hawkins, D. (2017)
Incorporation of tyrosine carboxyl groups and utilization of d-tyrosine in melanogenesis
Chen, Y. M., & Chavin, W. (1969) · Analytical Biochemistry · doi:10.1016/0003-2697(69)90060-8 · Cited by 14 · see citing works
The Phenylalanine and Tyrosine Requirements and Their Interrelationship for the Young Chick
Sasse, C. E., & Baker, D. H. (1972) · Poultry Science · doi:10.3382/ps.0511531 · Cited by 35 · see citing works
Tyrosine supplementation in phenylketonuria: Diurnal blood tyrosine levels and presumptive brain influx of tyrosine and other large neutral amino acids
Kalsner, L. R., Rohr, F., Strauss, K. A., et al. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.117576 · Cited by 26 · see citing works
Experimental Phenylketonuria: Replacement of Carboxyl Terminal Tyrosine by Phenylalanine in Infant Rat Brain Tubulin
Rodriguez, J. A., & Borisy, G. G. (1979) · Science · doi:10.1126/science.574315 · Cited by 23 · see citing works

Authors: Illouz, F., Laboureau-Soares, S., Dubois, S., Rohmer, V., & Rodien, P.
Affiliations: Centre Hospitalier Universitaire d'Angers (FR)
ORCID: Illouz, Frédéric
Rodien, Patrice
Venue: European Journal of Endocrinology
Publisher: Oxford University Press (OUP)
Published: 2009-03
Volume: 160
Issue: 3
Pages: 331-336
ISSN: 0804-4643 (ISSN-L)
1479-683X
DOI: 10.1530/eje-08-0648
OpenAlex: W2153747163
Cited by: 77
References: 40
Citations by year: 2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 3 · 2016: 11 · 2015: 7 · 2014: 8 · 2013: 6 · 2012: 3
FWCI: 1.11
Type: journal article
Language: en
Open access: closed
Locations: European Journal of Endocrinology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
Keywords: tyrosine kinase inhibitors, thyroid function tests, hypothyroidism, drug-induced thyroid dysfunction, thyroid hormone regulation, tyrosine kinase, cancer treatment side effects, thyroid function monitoring
MeSH terms: Humans, Hypothyroidism, Neoplasms, Protein-Tyrosine Kinases, Thyroid Function Tests, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tyrosine kinase inhibitors and modifications of thyroid function tests: a review

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks